Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin

por Kurimoto, M, Matsuoka, H, Hanaoka, N, Uneda, S, Murayama, T, Sonoki, T, Nakakuma, H
Publicado 2013

Residual Type 1 Immunity in Patients Genetically Deficient for Interleukin 12 Receptor β1 (IL-12Rβ1): Evidence for an IL-12Rβ1–Independent Pathway of IL-12 Responsiveness in Human...

por Verhagen, Claudia E., de Boer, Tjitske, Smits, Hermelijn H., Verreck, Frank A.W., Wierenga, Eddy A., Kurimoto, M., Lammas, D. Anthony, Kumararatne, Dinakanthe S., Sanal, Ozden, Kroon, Frank P., van Dissel, Jaap T., Sinigaglia, Francesco, Ottenhoff, Tom H.M.
Publicado 2000